Novartis

Camurus receives milestone from Novartis

Monday, September 16, 2013 08:45 AM

Novartis has exercised its option to acquire an exclusive license for the further development and worldwide commercialization of CAM2029 for treatment of patients with acromegaly and neuroendocrine tumors (NETs). The license also covers additional future products based on the Camurus' FluidCrystal Injection depot technology. Camurus is a research-based pharmaceutical company dedicated to developing therapeutics for diseases with high unmet medical needs.

More... »

Otsuka to acquire Astex Pharmaceuticals

Friday, September 6, 2013 03:00 PM

Otsuka Pharmaceuticals will acquire Astex Pharmaceuticals for approximately $886 million, through a tender offer for all outstanding Astex shares expected to close in the fourth quarter.

More... »

GenVec board restructures operations, withdraws plan of dissolution

Wednesday, September 4, 2013 12:11 PM

The board of directors of GenVec, a biopharmaceutical company using differentiated, proprietary technologies to create therapeutics and vaccines, has withdrawn the Plan of Complete Liquidation and Dissolution for the company, previously adopted May 24.

More... »

Decision Resources suggests breast cancer market to reach $15B by 2022

Friday, August 23, 2013 11:39 AM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of premium-priced agents will fuel 5% annual growth in the breast cancer market, with sales reaching more than $15 billion in 2022 in the U.S., France, Germany, Italy, Spain, the U.K. and Japan.

More... »

Ensemble Therapeutics, Novartis collaborate

Wednesday, August 7, 2013 11:51 AM

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, has initiated a two-part R&D collaboration with Novartis. The companies have entered into a strategic development agreement for Ensemble's most advanced proprietary program that targets the inflammatory cytokine IL-17, and for a new program to discover novel small molecule treatments against undisclosed drug targets specified by Novartis using Ensemble's proprietary drug discovery platforms.

More... »

Biogen Idec, Adimab expand collaboration

Friday, July 26, 2013 03:05 PM

Adimab, a provider of an integrated antibody discovery and optimization platform, has expanded its collaboration with Biogen Idec for the discovery of antibody-based therapeutics. 

More... »

Loxo Oncology, Array BioPharma in license, collaboration agreement

Thursday, July 11, 2013 09:10 AM

Loxo Oncology, a biopharmaceutical company established and funded by Aisling Capital, and Array BioPharma have announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets. 

More... »

Novartis, Biological E partner to deliver affordable vaccines to developing world

Monday, July 8, 2013 12:07 PM

Novartis has entered into a development and licensing agreement with Biological E (BioE), a biopharmaceutical company based in India, for two vaccines to protect against typhoid and paratyphoid fevers. The agreement advances the Novartis goal to deliver accessible and affordable vaccines that address unmet medical need in endemic regions.

More... »

Amgen, Novartis join Atlas Venture Fund IX as corporate strategic partners

Friday, May 17, 2013 12:25 PM

Atlas Venture, an early-stage venture capital firm that invests in technology and life sciences companies, has entered into Corporate Strategic Partnership (CSP) agreements with both Amgen, through its venture capital fund, Amgen Ventures, and Novartis. The CSP agreements are in conjunction with the closing of Atlas IX in which Amgen Ventures and Novartis are new limited partners. 

More... »

Novartis’s LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer

Monday, March 18, 2013 11:30 AM

The FDA has granted Novartis’ investigational compound LDK378 Breakthrough Therapy designation for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during treatment with, or were intolerant to, crizotinib.

More... »